• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PPARγ 在乳腺癌中的抗癌活性具有一定的条件依赖性。

Anticancer activities of PPARγ in breast cancer are context-dependent.

机构信息

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA.

出版信息

Am J Pathol. 2013 Jun;182(6):1972-5. doi: 10.1016/j.ajpath.2013.03.005. Epub 2013 Apr 22.

DOI:10.1016/j.ajpath.2013.03.005
PMID:23619477
Abstract

This Commentary highlights the article by Nakles et al, who described that PPARγ activation suppresses non-invasive tumor development and induces ER-positivity without affecting invasive tumor development.

摘要

本述评强调了 Nakles 等人的文章，他们描述了 PPARγ 激活抑制非侵袭性肿瘤发展并诱导 ER 阳性而不影响侵袭性肿瘤发展。

相似文献

1
Anticancer activities of PPARγ in breast cancer are context-dependent.PPARγ 在乳腺癌中的抗癌活性具有一定的条件依赖性。
Am J Pathol. 2013 Jun;182(6):1972-5. doi: 10.1016/j.ajpath.2013.03.005. Epub 2013 Apr 22.
2
The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.PPARγ 激动剂 efatutazone 增加了全长 BRCA1 缺失伴 TP53 杂合不足起始的高分化乳腺肿瘤亚型谱。
Am J Pathol. 2013 Jun;182(6):1976-85. doi: 10.1016/j.ajpath.2013.02.006. Epub 2013 May 8.
3
Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis.过氧化物酶体增殖物激活受体δ和γ激动剂在乳腺癌发生过程中对肿瘤分化和进展有不同影响。
Cancer Res. 2005 May 1;65(9):3950-7. doi: 10.1158/0008-5472.CAN-04-3990.
4
Stromal adipocyte PPARγ protects against breast tumorigenesis.基质脂肪细胞 PPARγ 可预防乳腺癌发生。
Carcinogenesis. 2012 Jul;33(7):1412-20. doi: 10.1093/carcin/bgs173. Epub 2012 May 11.
5
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone.巨噬细胞过氧化物酶体增殖物激活受体γ抑制Gpr132以介导罗格列酮的抗肿瘤作用。
Elife. 2016 Oct 3;5:e18501. doi: 10.7554/eLife.18501.
6
[Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].[噻唑烷二酮类和非噻唑烷二酮类PPARγ激动剂的近期研发趋势]
Nihon Rinsho. 2010 Feb;68(2):249-55.
7
Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.在PTEN杂合子小鼠模型中，使用过氧化物酶体增殖物激活受体γ激动剂罗格列酮对子宫内膜增生进行一级化学预防。
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):329-38. doi: 10.1111/j.1525-1438.2007.01002.x.
8
Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.依伐他唑酮对乳腺肿瘤的影响因Brca1剂量而异。
Endocr Relat Cancer. 2018 Dec 1;25(12):L53-L57. doi: 10.1530/ERC-18-0299.
9
Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression.乳腺上皮特异性PPARγ信号传导及激活在乳腺肿瘤进展过程中的相反作用。
Mol Cancer. 2015 Apr 15;14:85. doi: 10.1186/s12943-015-0347-8.
10
A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis.
Cancer Res. 1999 Nov 15;59(22):5671-3.

引用本文的文献

1
Recent Advances in the Knowledge of the Mechanisms of Leptin Physiology and Actions in Neurological and Metabolic Pathologies.瘦素生理学及其在神经和代谢病理中的作用机制的最新进展。
Int J Mol Sci. 2023 Jan 11;24(2):1422. doi: 10.3390/ijms24021422.
2
Obesity, leptin, and deregulation of microRNA in lipid metabolisms: their contribution to breast cancer prognosis.肥胖、瘦素与脂质代谢中微小RNA的失调：它们对乳腺癌预后的影响。
Diabetol Metab Syndr. 2021 Jan 22;13(1):10. doi: 10.1186/s13098-020-00621-4.
3
Diet and Pro12Ala Polymorphism Interactions in Relation to Cancer Risk: A Systematic Review.
饮食与 Pro12Ala 多态性相互作用与癌症风险的关系：系统评价。
Nutrients. 2021 Jan 18;13(1):261. doi: 10.3390/nu13010261.
4
ERRα inhibitor acts as a potential agonist of PPARγ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer.ERRα 抑制剂作为 PPARγ 的潜在激动剂，可诱导子宫内膜癌细胞凋亡并抑制细胞增殖。
Aging (Albany NY). 2020 Nov 10;12(22):23029-23046. doi: 10.18632/aging.104049.
5
Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.依伐他唑酮对乳腺肿瘤的影响因Brca1剂量而异。
Endocr Relat Cancer. 2018 Dec 1;25(12):L53-L57. doi: 10.1530/ERC-18-0299.
6
A Systems Biology Approach to Understanding the Pathophysiology of High-Grade Serous Ovarian Cancer: Focus on Iron and Fatty Acid Metabolism.一种系统生物学方法来理解高级别浆液性卵巢癌的病理生理学：关注铁和脂肪酸代谢。
OMICS. 2018 Jul;22(7):502-513. doi: 10.1089/omi.2018.0060.
7
Peroxisome proliferator-activated receptor-γ agonist-mediated inhibition of cell growth is independent of apoptosis in human epidermoid carcinoma A431 cells.过氧化物酶体增殖物激活受体γ激动剂介导的细胞生长抑制与人表皮样癌A431细胞的凋亡无关。
Oncol Lett. 2018 May;15(5):6578-6584. doi: 10.3892/ol.2018.8136. Epub 2018 Feb 28.
8
Alcohol consumption and breast tumor gene expression.饮酒与乳腺癌基因表达。
Breast Cancer Res. 2017 Sep 12;19(1):108. doi: 10.1186/s13058-017-0901-y.
9
Role of n-3 Polyunsaturated Fatty Acids and Exercise in Breast Cancer Prevention: Identifying Common Targets.n-3多不饱和脂肪酸与运动在乳腺癌预防中的作用：确定共同靶点
Nutr Metab Insights. 2016 Oct 30;9:71-84. doi: 10.4137/NMI.S39043. eCollection 2016.